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objectives: The everolimus-eluting bioresorbable scaffold (Absorb; Abbott vascular, CA, USA) has been shown to be effective in the context of first-
in-man trials including simple lesions. However, limited data exist on patients who have undergone scaffolding of long lesions in native coronary 
arteries.
Methods: Since September 1st 2012, our institution commenced the use of Absorb scaffold in patients with complex lesions including a long 
lesion (>32mm in length), a calcified lesion and a bifurcation lesion. Patients presenting with stable angina, unstable angina and non-ST elevation 
myocardial infarction (MI) were included. Up to July 26, 2013, in total 181 patients with 240 lesions were exclusively treated with Absorb scaffolds. 
Amongst those, the current analysis included 69 patients (77 lesions) who received Absorb scaffold(s) in long lesion(s) with obstruction length(s) on 
quantitative coronary angiography (QCA) of greater than 32mm.
results: The mean age was 60.8±10.0 years old, and 83% of the treated long lesions were B2/C according to the AHA/ACC lesion classification, 
while 73% had on angiography moderate to severe calcification. On pre-procedural QCA, the lesion was on average as long as 42.8±23.7 mm 
with a proximal Dmax and a distal Dmax of 2.87±1.17 mm and 2.52±1.08 mm respectively, while pre-procedural MLD was 0.91±0.84 mm. The 
mean number of implanted scaffolds per lesion was 2.3 ±1.7. In 72 lesions (93.5%), scaffolds were placed with overlap. On post-procedural QCA, 
in-scaffold MLD was 2.28±1.12 mm, resulting in an acute gain of 1.3±1.0 mm. The delivery and procedural success rate was 97.4% and 97.4% 
respectively. Major in-hospital adverse events occurred in 1 patient (1.4%, periprocedural MI). An interim analysis showed that all-cause mortality at 
6 months was 2.8% with one case of spontaneous MI and one case of definite or probable scaffold thrombosis.
conclusion: The angiographic and acute clinical results demonstrated that the placement of bioresorbable scaffolds in long lesions is feasible. The 
interim analysis suggested that this strategy seems to be safe in mid-term follow up. The complete 6-month outcomes are being collected and will 
be presented at the time of the meeting.
